Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis

Vaccine

Volumn 25, Issue 29, 2007, Pages 5433-5440

  De Wals, Philippe ^a   Coudeville, Laurent ^b   Trottier, Pierre ^a   Chevat, Catherine ^b   Erickson, Lonny J ^c   Nguyen, Van Hung ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b SANOFI PASTEUR   (France)

^c Agency for Health Services and Technology Assessment   (Canada)

Author keywords

Conjugate vaccine; Cost effectiveness; Economics; Meningococcus

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FATALITY; HERD IMMUNITY; HUMAN; INCIDENCE; MENINGOCOCCOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVACCINATION; SIMULATION; SPAIN; STATISTICAL MODEL; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED;

EID: 34250819829     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.071     Document Type: Article

References (51)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 (2001) 1378-1388
2. Jones D. Epidemiology of meningococcal disease in Europe and the USA. In: Cartwright K. (Ed). Meningococcal disease (1995), John Wiley & Sons, Chichester, UK 147-158
3. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 5 (2006) 269-275
4. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 54 RR-7 (2005) 1-21
5. Mueller J.E., Borrow R., and Gessner B.D. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines 5 (2006) 319-336
6. Danzig L. Meningococcal vaccines. Paed Infect Dis J 23 Suppl (2004) 285-292
7. Girard M.P., Preziozi M.P., Aguado M.T., and Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 24 (2006) 4692-4700
8. De Wals P., Trottier P., and Pépin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 24 (2006) 3500-3504
9. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
10. Larrauri A., Cano R., Garcia M., and de Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23 (2005) 4097-4100
11. Zhang Q., Choo S., Everard J., Jennings R., and Finn A. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 68 (2000) 2692-2697
12. Zhang Q., Pettitt E., Burkinshaw R., Race G., Shaw L., and Finn A. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J 21 (2002) 209-213
13. Cartwright K. Meningococcal carriage and disease. In: Cartwright K. (Ed). Meningococcal disease (1995), John Wiley & Sons, Chichester, UK 71-114
14. Trotter C.L., Gay N.J., and Edmunds W.J. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162 (2005) 89-100
15. Maiden M.C., Stuart J.M., and for The U.K. Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 (2002) 1829-1830
16. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 (2003) 365-366
17. National Advisory Committee on immunization (NACI). Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. Can Commun Dis Rep 33 ACS-3 (2007) 1-24
18. Deeks S., Kertesz D., Ryan A., Johnson W., and Ashton F. Surveillance of invasive meningococcal disease in Canada, 1995-1996. Can Commun Dis Rep 23 16 (1997) 121-125
19. Squires S.G., Pelletier L., Mungai M., Tsang R., Collins F., and Stoltz J. Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 26 21 (2000) 177-182
20. Squires S.G., and Deeks S.L. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January 1999 through 31 December 2001. Can Commun Dis Rep 30 (2004) 17-28
21. Lorange M, Jetté L. Surveillance des infections envahissantes à Neisseria meningitidis. Rapport annuel 2001. Quebec City: Institut national de santé publique, Laboratoire de santé publique du Québec; 2002. Available at: http://www.inspq.qc.ca/pdf/publications/113_Neisseriameningitidis2001.pdf.
22. Rivest P., Sagot B., and Bédard L. Evaluation of the completeness of reporting of invasive meningococcal disease. Can J Public Health 90 (1999) 250-251
23. Stovall S.H., and Schutz G.E. Meningococcal infections in children in Arkansas. Pediatr Infect Dis J 21 (2002) 366-370
24. Erickson L.J., De Wals P., McMahon J., and Heim S. Complications of meningococcal disease in college students. Clin Infect Diseases 33 (2001) 737-739
25. Anderson R.M., and May R.M. Infectious diseases of humans: dynamics and control (1991), Oxford University Press, Oxford
26. Coen P.G., Cartwright K., and Stuart J. Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica. Int J Epidemiol 29 (2000) 180-188
27. De Wals P., and Erickson L. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec. Vaccine 20 (2002) 2840-2844
28. Meningococcal disease prevention and control strategies for practice-based physicians: a joint statement of the Infectious Diseases and Immunization Committee, Canadian Paediatric Society, and the Committee on Infectious Diseases; 1994-1995. Available at http://www.cps.ca/english/statements/ID/id96-03.htm.
29. Official Disability Guidelines, 2003. 8th ed. (2003), Work Loss Data Institute, Corpus Christi, TX
30. Williams M.O. Long-term cost comparison of major limb salvage using the Ilizarov method versus amputation. Clin Orthop 301 (1994) 156-158
31. Mohr P.E., Feldman J.J., and Dunbar J.L. The societal costs of severe to profound hearing loss in the United States. Int J Technol Assess Health Care 16 (2000) 1120-1135
32. Ploth D.W., Shepp P.H., Counts C., and Hutchison F. Prospective analysis of global costs for maintenance of patients with ESRD. Am J Kidney Dis 42 (2003) 12-21
33. Wooten A. Mental retardation services FY2004 statistical summary. Fairfax-Falls Church Community Services Board, 2004. Available at: http://www.co.fairfax.va.us/service/csb/mrs/mrsbudata.htm.
34. Bos J.M., Rumke H.C., Welte R., Postma M.J., and Jager J.C. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Vaccine 20 (2002) 202-207
35. Erickson L., and De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 26 (1998) 1159-1164
36. Ontario Drug Benefit Formulary. Ontario Ministry of Health and Long-Term Care, 2004. Available at: http://www.health.gov.on.ca/.
37. Ontario Schedule of Benefits: Physician Services under the Health Insurance Act. Ontario Ministry of Health and Long-Term Care, revised to November 1, 2004.
38. Statistics Canada. Labour force characteristics by age and sex, 2004. Available at http://www.statcan.ca/english/Pgdb/labor20a.htm.
39. Statistics Canada. Canadian statistics: household size; 2001. Available at http://www.statcan.ca/english/Pgdb/famil53b.htm.
40. Statistics Canada. Canadian statistics; 2001. Available at http://www.statcan.ca/english/Pgdb/labor50b.htm.
41. Recommendation from the National Advisory Committee on Immunization (NACI). Immunization schedules, 2006. Available at: http://www.phac-aspc.gc.ca/im/is-cv/index.html.
42. De Wals P., Nguyen V.H., Erickson L.J., Guay M., Drapeau J., and St-Laurent J. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 22 (2004) 1233-1240
43. Trotter C., and Edmunds W.J. Modelling cost-effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 324 (2002) 1-6
44. Sturgis P., Thomas R., Purdon S., Bridgewood A., and Dodd T. Comparative review and assessment of key health state measures of the general population (2001), Department of Health, London, UK
45. Healy C.M., Butler K.M., Smith E.O., Hensey O.P., Bate T., Moloney A.C., et al. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. Clin Infect Dis 34 (2002) 1323-1330
46. Oostenbrink R., Moll H.A., and Essink-Bot M. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis. A head-to-head comparison. J Clin Epidemiol 55 (2002) 791-799
47. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276 (1996) 1409-1415
48. Statistics Canada. Population estimates based on 1996 Canadian Population Census, 2006. Available at: http://www.statscan.ca/.
49. De Wals P., Deceuninck G., Boulianne N., and De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 292 (2004) 2491-2494
50. National Advisory Committee on Immunization (NACI). Update on meningococcal conjugate vaccines. Can Commun Dis Rep 31 ACS-3 (2005) 1-4
51. ® meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR 55 (2006) 1120-1124